Treatment for chemical burning using liquid crystalline nanoparticles as an ophthalmic delivery system for pirfenidone
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFMG |
Texto Completo: | https://doi.org/10.1016/j.ijpharm.2019.118466 http://hdl.handle.net/1843/51758 https://orcid.org/0000-0002-4506-7570 https://orcid.org/0000-0002-1161-8936 https://orcid.org/0000-0003-3007-9795 https://orcid.org/0000-0003-1382-2487 https://orcid.org/0000-0002-6449-7904 https://orcid.org/0000-0001-5287-455X https://orcid.org/0000-0002-8703-4283 https://orcid.org/0000-0003-3588-0178 |
Resumo: | Some recent studies have shown that pirfenidone (PFD) has favorable results in the healing process of the cornea. However, PFD in solution exhibits short half-life after topical application, and in this context, a liquid crystal nanoparticle system containing PFD (PFD-LCNPs) was developed. The nanoparticles were characterized by transmission electron microscopy, atomic force microscopy, small angle X-ray diffraction and polarized light microscopy. The PFD-LCNPs had particle size and zeta potential of 247.3 nm and −33.60 mV (stores at 4 °C), respectively, and 257.5 nm and −46.00 mV (stored at 25 °C), respectively. The pH of the formulation was 6.9 and the encapsulation efficiency was 35.9%. The in vitro release profiles indicated that PFD sustained release from PFD-LCNPs for up to 12 h. In vitro study of ocular irritation (HET-CAM test) concluded that components of the formulation are well tolerated for ocular administration. Corneal re-epithelialization time after chemical burning was significantly reduced in rabbits treated with PFD-loaded LCNPs when compared to the group treated with a vehicle. In addition, the anti-inflammatory action of pirfenidone was observed by reducing myeloperoxidase activity (MPO) and inflammatory cells in the histology of the tissues of animals treated with PFD-LCNPs. These findings indicated that the PFD-LCNPs might have the potential for effective ocular drug delivery. |
id |
UFMG_e889f13670ea3eb7496ab1d233bb77ec |
---|---|
oai_identifier_str |
oai:repositorio.ufmg.br:1843/51758 |
network_acronym_str |
UFMG |
network_name_str |
Repositório Institucional da UFMG |
repository_id_str |
|
spelling |
Treatment for chemical burning using liquid crystalline nanoparticles as an ophthalmic delivery system for pirfenidoneOcular chemical burnsPirfenidoneLiquid crystalline nanoparticlesCorneaWound healingQueimaduras químicasNanopartículasCórneaCicatrização de feridasSome recent studies have shown that pirfenidone (PFD) has favorable results in the healing process of the cornea. However, PFD in solution exhibits short half-life after topical application, and in this context, a liquid crystal nanoparticle system containing PFD (PFD-LCNPs) was developed. The nanoparticles were characterized by transmission electron microscopy, atomic force microscopy, small angle X-ray diffraction and polarized light microscopy. The PFD-LCNPs had particle size and zeta potential of 247.3 nm and −33.60 mV (stores at 4 °C), respectively, and 257.5 nm and −46.00 mV (stored at 25 °C), respectively. The pH of the formulation was 6.9 and the encapsulation efficiency was 35.9%. The in vitro release profiles indicated that PFD sustained release from PFD-LCNPs for up to 12 h. In vitro study of ocular irritation (HET-CAM test) concluded that components of the formulation are well tolerated for ocular administration. Corneal re-epithelialization time after chemical burning was significantly reduced in rabbits treated with PFD-loaded LCNPs when compared to the group treated with a vehicle. In addition, the anti-inflammatory action of pirfenidone was observed by reducing myeloperoxidase activity (MPO) and inflammatory cells in the histology of the tissues of animals treated with PFD-LCNPs. These findings indicated that the PFD-LCNPs might have the potential for effective ocular drug delivery.CNPq - Conselho Nacional de Desenvolvimento Científico e TecnológicoFAPEMIG - Fundação de Amparo à Pesquisa do Estado de Minas GeraisCAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível SuperiorINCT – Instituto nacional de ciência e tecnologia (Antigo Instituto do Milênio)FAPESP - Fundação de Amparo à Pesquisa do Estado de São PauloUniversidade Federal de Minas GeraisBrasilFAR - DEPARTAMENTO DE PRODUTOS FARMACÊUTICOSICX - DEPARTAMENTO DE FÍSICAUFMG2023-04-10T20:02:46Z2023-04-10T20:02:46Z2019info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlepdfapplication/pdfhttps://doi.org/10.1016/j.ijpharm.2019.1184661873-3476http://hdl.handle.net/1843/51758https://orcid.org/0000-0002-4506-7570https://orcid.org/0000-0002-1161-8936https://orcid.org/0000-0003-3007-9795https://orcid.org/0000-0003-1382-2487https://orcid.org/0000-0002-6449-7904https://orcid.org/0000-0001-5287-455Xhttps://orcid.org/0000-0002-8703-4283https://orcid.org/0000-0003-3588-0178engInternational Journal of PharmaceuticsRummenigge Oliveira SilvaArmando da Silva Cunha JúniorBruna Lopes da CostaFlávia Rodrigues da SilvaCarolina Nunes da SilvaMayara Rodrigues Brandão de PaivaLays Fernanda Nunes DouradoÂngelo Malachias de SouzaAdriano Antunes de Souza AraújoPaula Santos Nunesinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFMGinstname:Universidade Federal de Minas Gerais (UFMG)instacron:UFMG2023-04-10T22:33:19Zoai:repositorio.ufmg.br:1843/51758Repositório InstitucionalPUBhttps://repositorio.ufmg.br/oairepositorio@ufmg.bropendoar:2023-04-10T22:33:19Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)false |
dc.title.none.fl_str_mv |
Treatment for chemical burning using liquid crystalline nanoparticles as an ophthalmic delivery system for pirfenidone |
title |
Treatment for chemical burning using liquid crystalline nanoparticles as an ophthalmic delivery system for pirfenidone |
spellingShingle |
Treatment for chemical burning using liquid crystalline nanoparticles as an ophthalmic delivery system for pirfenidone Rummenigge Oliveira Silva Ocular chemical burns Pirfenidone Liquid crystalline nanoparticles Cornea Wound healing Queimaduras químicas Nanopartículas Córnea Cicatrização de feridas |
title_short |
Treatment for chemical burning using liquid crystalline nanoparticles as an ophthalmic delivery system for pirfenidone |
title_full |
Treatment for chemical burning using liquid crystalline nanoparticles as an ophthalmic delivery system for pirfenidone |
title_fullStr |
Treatment for chemical burning using liquid crystalline nanoparticles as an ophthalmic delivery system for pirfenidone |
title_full_unstemmed |
Treatment for chemical burning using liquid crystalline nanoparticles as an ophthalmic delivery system for pirfenidone |
title_sort |
Treatment for chemical burning using liquid crystalline nanoparticles as an ophthalmic delivery system for pirfenidone |
author |
Rummenigge Oliveira Silva |
author_facet |
Rummenigge Oliveira Silva Armando da Silva Cunha Júnior Bruna Lopes da Costa Flávia Rodrigues da Silva Carolina Nunes da Silva Mayara Rodrigues Brandão de Paiva Lays Fernanda Nunes Dourado Ângelo Malachias de Souza Adriano Antunes de Souza Araújo Paula Santos Nunes |
author_role |
author |
author2 |
Armando da Silva Cunha Júnior Bruna Lopes da Costa Flávia Rodrigues da Silva Carolina Nunes da Silva Mayara Rodrigues Brandão de Paiva Lays Fernanda Nunes Dourado Ângelo Malachias de Souza Adriano Antunes de Souza Araújo Paula Santos Nunes |
author2_role |
author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Rummenigge Oliveira Silva Armando da Silva Cunha Júnior Bruna Lopes da Costa Flávia Rodrigues da Silva Carolina Nunes da Silva Mayara Rodrigues Brandão de Paiva Lays Fernanda Nunes Dourado Ângelo Malachias de Souza Adriano Antunes de Souza Araújo Paula Santos Nunes |
dc.subject.por.fl_str_mv |
Ocular chemical burns Pirfenidone Liquid crystalline nanoparticles Cornea Wound healing Queimaduras químicas Nanopartículas Córnea Cicatrização de feridas |
topic |
Ocular chemical burns Pirfenidone Liquid crystalline nanoparticles Cornea Wound healing Queimaduras químicas Nanopartículas Córnea Cicatrização de feridas |
description |
Some recent studies have shown that pirfenidone (PFD) has favorable results in the healing process of the cornea. However, PFD in solution exhibits short half-life after topical application, and in this context, a liquid crystal nanoparticle system containing PFD (PFD-LCNPs) was developed. The nanoparticles were characterized by transmission electron microscopy, atomic force microscopy, small angle X-ray diffraction and polarized light microscopy. The PFD-LCNPs had particle size and zeta potential of 247.3 nm and −33.60 mV (stores at 4 °C), respectively, and 257.5 nm and −46.00 mV (stored at 25 °C), respectively. The pH of the formulation was 6.9 and the encapsulation efficiency was 35.9%. The in vitro release profiles indicated that PFD sustained release from PFD-LCNPs for up to 12 h. In vitro study of ocular irritation (HET-CAM test) concluded that components of the formulation are well tolerated for ocular administration. Corneal re-epithelialization time after chemical burning was significantly reduced in rabbits treated with PFD-loaded LCNPs when compared to the group treated with a vehicle. In addition, the anti-inflammatory action of pirfenidone was observed by reducing myeloperoxidase activity (MPO) and inflammatory cells in the histology of the tissues of animals treated with PFD-LCNPs. These findings indicated that the PFD-LCNPs might have the potential for effective ocular drug delivery. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019 2023-04-10T20:02:46Z 2023-04-10T20:02:46Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://doi.org/10.1016/j.ijpharm.2019.118466 1873-3476 http://hdl.handle.net/1843/51758 https://orcid.org/0000-0002-4506-7570 https://orcid.org/0000-0002-1161-8936 https://orcid.org/0000-0003-3007-9795 https://orcid.org/0000-0003-1382-2487 https://orcid.org/0000-0002-6449-7904 https://orcid.org/0000-0001-5287-455X https://orcid.org/0000-0002-8703-4283 https://orcid.org/0000-0003-3588-0178 |
url |
https://doi.org/10.1016/j.ijpharm.2019.118466 http://hdl.handle.net/1843/51758 https://orcid.org/0000-0002-4506-7570 https://orcid.org/0000-0002-1161-8936 https://orcid.org/0000-0003-3007-9795 https://orcid.org/0000-0003-1382-2487 https://orcid.org/0000-0002-6449-7904 https://orcid.org/0000-0001-5287-455X https://orcid.org/0000-0002-8703-4283 https://orcid.org/0000-0003-3588-0178 |
identifier_str_mv |
1873-3476 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
International Journal of Pharmaceutics |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
pdf application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais Brasil FAR - DEPARTAMENTO DE PRODUTOS FARMACÊUTICOS ICX - DEPARTAMENTO DE FÍSICA UFMG |
publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais Brasil FAR - DEPARTAMENTO DE PRODUTOS FARMACÊUTICOS ICX - DEPARTAMENTO DE FÍSICA UFMG |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFMG instname:Universidade Federal de Minas Gerais (UFMG) instacron:UFMG |
instname_str |
Universidade Federal de Minas Gerais (UFMG) |
instacron_str |
UFMG |
institution |
UFMG |
reponame_str |
Repositório Institucional da UFMG |
collection |
Repositório Institucional da UFMG |
repository.name.fl_str_mv |
Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG) |
repository.mail.fl_str_mv |
repositorio@ufmg.br |
_version_ |
1823247947542822912 |